Table 1 Clinical and laboratory characteristics of 776 patients with MDS.

From: Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre

Characteristics

ARC < 20 × 109/L (N = 169)

ARC ≥ 20 × 109/L (N = 607)

Total (N = 776)

p value

Sex, n (%)

   

0.046

Male

119 (70.4%)

375 (61.8%)

494 (63.7%)

 

Female

50 (29.6%)

232 (38.2%)

282 (36.35%)

 

Age, median (range), y

56 (16–83)

52 (14–83)

54 (14–83)

0.032

Age ≥60 years, n (%)

73 (43.2%)

199 (32.8%)

272 (35.1%)

0.014

WHO classification 2016, n (%)

   

0.101

MDS-SLD

4 (2.4%)

30 (4.9%)

34 (4.4%)

 

MDS-RS-SLD

4 (2.4%)

18 (3.0%)

22 (2.8%)

 

MDS-MLD

71 (42.0%)

307 (50.6%)

378 (48.7%)

 

MDS-RS-MLD

5 (3.0%)

10 (1.6%)

15 (1.9%)

 

MDS-EB1

39 (23.1%)

114 (18.8%)

153 (19.7%)

 

MDS-EB2

41 (24.3%)

104 (17.1%)

145 (18.7%)

 

MDS with isolated del (5q)

0

7 (1.2%)

7 (0.9%)

 

MDS-U

5 (3.0%)

17 (2.8%)

22 (2.8%)

 

Hb, median (range), g/L

64 (31–138)

83 (38–155)

78 (31–155)

<0.001

WBC, median (range), ×109/L

2.51 (0.71–21.17)

2.83 (0.61–20.42)

2.75 (0.61–21.17)

0.007

ANC, median (range), ×109/L

0.99 (0.04–13.18)

1.19 (0–17.37)

1.15 (0–17.37)

0.002

PLT, median (range), ×109/L

51 (2–536)

63 (2–694)

60 (2–694)

0.012

BM erythroblasts, median (range), %

20 (0–75)

35 (0–92.5)

31 (0–92.5)

<0.001

Sum of proerythroblast and basophilic erythroblast(E1), median (range), %

1 (0–30)

1.5 (0–18.5)

1.5 (0–30)

0.009

Sum of polychromatic and orthochromatic erythroblast (E2), median (range), %

17.5 (0–67)

32 (0–88)

29 (0–88)

<0.001

Ratio of E1 to E2, median (range)

0.052 (0–1.75)

0.05 (0–2)

0.05 (0–2)

0.305

BM blast, median (range), %

3.5 (0–19.5)

2.5 (0–19.5)

2.5 (0–19.5)

0.005

IPSS-R karyotype, n (%), N = 678

   

<0.001

Very good

1 (0.7%)

7 (1.3%)

8 (1.2%)

 

Good

69 (48.6%)

313 (58.4%)

382 (56.3%)

 

Intermediate

26 (18.3%)

138 (25.7%)

164 (24.2%)

 

Poor

11 (7.7%)

29 (5.4%)

40 (5.9%)

 

Very poor

35 (24.6%)

49 (9.1%)

84 (12.4%)

 

Complex karyotype, n (%)

39 (27.5%)

68 (12.7%)

107 (15.8%)

<0.001

IPSS-R risk group, n (%), N = 678

   

<0.001

Very low

0

21 (3.9%)

21 (3.1%)

 

Low

21 (14.8%)

148 (27.6%)

169 (24.9%)

 

Intermediate

41 (28.9%)

175 (32.6%)

216 (31.9%)

 

High

30 (21.1%)

122 (22.8%)

152 (22.4%)

 

Very high

50 (35.2%)

70 (13.1%)

120 (17.7%)

 

IPSS-R two groups, n (%)

   

<0.001

Lower-risk

40 (28.2%)

245 (45.7%)

285 (42.0%)

 

Higher-risk

102 (71.8%)

291 (54.3%)

393 (58.0%)

 
  1. MDS myelodysplastic syndrome, ARC absolute reticulocyte count, MDS-SLD MDS with single lineage dysplasia, MDS-RS-SLD MDS with ring sideroblasts with single lineage dysplasia, MDS-MLD MDS with multilineage dysplasia, MDS-RS-MLD MDS with ring sideroblasts with multilineage dysplasia, MDS-EB1 MDS with excess blasts-1, MDS-EB2 MDS with excess blasts-2, MDS-U MDS unclassifiable, Hb haemoglobin, WBC white blood coun, ANC absolute neutrophil count, PLT platelet count, BM bone marrow, IPSS-R Revised International Prognostic Scoring System.
Back to article page